A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Conditions
Advanced Solid Tumor · NSCLC (Non-small Cell Lung Cancer) · Renal Cancer · Mesothelioma · Non-Small Cell Squamous Lung Cancer · Non-small Cell Lung Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Phoenix, Arizona, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
University of Chicago, Chicago, Illinois, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology Houston, Houston, Texas, United States
NEXT Oncology Dallas, Irving, Texas, United States
NEXT Oncology Virginia, Fairfax, Virginia, United States
Western General Hospital - NHS Lothian, Edinburgh, United Kingdom
The Royal Marsden NHS Foundation and Trust, London, United Kingdom
Study leads
Udai Banerji, Prof
Principal Investigator
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Gerald Falchook, MD
Principal Investigator
Sarah Cannon Cancer Institute, HealthOne Denver